Search Browse Earnings

Upstream Bio, Inc.

Nasdaq:UPB

Pharmaceutical Preparations·WALTHAM, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Upstream Bio, Inc. — SlamSEC

Revenue

$2.4M

FY 2024

Adj. EBITDA

-$40.1M

-1682.9% margin

FY 2024

Net Income

-$20.5M

-862.9% margin

FY 2024

EPS (Diluted)

-$12.95

FY 2024

Stock Price

$9.23

-2.2%

2026-03-13

52W Range

$5.14 – $33.68

P/E Ratio

-0.7x

Market Cap

$498.8M

Cash

$25.8M

FY 2024

Total Debt

—

Net Cash

$25.8M

FY 2024

Enterprise Value

$472.9M

Debt / EBITDA

0.6x

FY 2024

EV / EBITDA

-11.8x

Employees

—